Oriola Oyj (ORIOLA) Stock Overview
Engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
ORIOLA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Oriola Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.92 |
| 52 Week High | €1.26 |
| 52 Week Low | €0.88 |
| Beta | 0.48 |
| 1 Month Change | 2.35% |
| 3 Month Change | -9.23% |
| 1 Year Change | -15.75% |
| 3 Year Change | -32.02% |
| 5 Year Change | -51.07% |
| Change since IPO | -53.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORIOLA | FI Healthcare | FI Market | |
|---|---|---|---|
| 7D | -0.7% | 1.7% | -0.8% |
| 1Y | -15.7% | -11.6% | 32.0% |
Return vs Industry: ORIOLA underperformed the Finnish Healthcare industry which returned -11.6% over the past year.
Return vs Market: ORIOLA underperformed the Finnish Market which returned 32% over the past year.
Price Volatility
| ORIOLA volatility | |
|---|---|
| ORIOLA Average Weekly Movement | 2.3% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FI Market | 7.7% |
| 10% least volatile stocks in FI Market | 3.2% |
Stable Share Price: ORIOLA has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: ORIOLA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1907 | 800 | Katarina Gabrielson | oriola.com |
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services.
Oriola Oyj Fundamentals Summary
| ORIOLA fundamental statistics | |
|---|---|
| Market cap | €172.49m |
| Earnings (TTM) | -€23.80m |
| Revenue (TTM) | €1.91b |
Is ORIOLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORIOLA income statement (TTM) | |
|---|---|
| Revenue | €1.91b |
| Cost of Revenue | €1.74b |
| Gross Profit | €167.90m |
| Other Expenses | €191.70m |
| Earnings | -€23.80m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 17, 2026
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 8.81% |
| Net Profit Margin | -1.25% |
| Debt/Equity Ratio | 67.0% |
How did ORIOLA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 19:21 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oriola Oyj is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Iiris Theman | Carnegie Investment Bank AB |
| Panu Laitinmäki | Danske Bank |
| Iiris Theman | DNB Carnegie |